Does the media refer more to SMMT or MRK?

In the previous week, Merck & Co., Inc. had 49 more articles in the media than Summit Therapeutics. MarketBeat recorded 63 mentions for Merck & Co., Inc. and 14 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.11 beat Summit Therapeutics' score of 0.35 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Merck & Co., Inc. 43 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SMMT or LPA?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Logistic Properties of the Americas $50.13M 1.85 $10.50M N/A N/A

Which has better valuation & earnings, SMMT or RVMD?

Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Revolution Medicines N/A N/A -$1.13B -$7.07 N/A

Is SMMT or RVMD more profitable?

Revolution Medicines' return on equity of -83.22% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Revolution Medicines N/A -83.22% -59.06%

Does the media refer more to SMMT or RVMD?

In the previous week, Revolution Medicines had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 23 mentions for Revolution Medicines and 14 mentions for Summit Therapeutics. Revolution Medicines' average media sentiment score of 1.39 beat Summit Therapeutics' score of 0.35 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 19 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ONC or SMMT?

In the previous week, BeOne Medicines and BeOne Medicines both had 14 articles in the media. BeOne Medicines' average media sentiment score of 0.90 beat Summit Therapeutics' score of 0.35 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Summit Therapeutics (SMMT) Competitors

$13.02 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$13.10 +0.08 (+0.61%)

As of 07/31/2026 07:54 PM Eastern

Compare

SMMT vs. MRK, LPA, RVMD, ONC, and TEVA

Should you buy Summit Therapeutics stock or one of its competitors? MarketBeat compares Summit Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Summit Therapeutics include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), Revolution Medicines (RVMD), BeOne Medicines (ONC), and Teva Pharmaceutical Industries (TEVA).

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summit Therapeutics (NASDAQ:SMMT) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Merck & Co., Inc. has a net margin of 13.59% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 27.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Merck & Co., Inc.	13.59%	27.55%	10.73%

Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Summit Therapeutics presently has a consensus price target of $26.15, suggesting a potential upside of 100.88%. Merck & Co., Inc. has a consensus price target of $134.50, suggesting a potential upside of 3.07%. Given Summit Therapeutics' higher possible upside, equities analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.65

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Merck & Co., Inc.	$65.01B	4.96	$18.25B	$3.55	36.76

In the previous week, Merck & Co., Inc. had 49 more articles in the media than Summit Therapeutics. MarketBeat recorded 63 mentions for Merck & Co., Inc. and 14 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.11 beat Summit Therapeutics' score of 0.35 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Merck & Co., Inc.	43 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Merck & Co., Inc. beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summit Therapeutics (NASDAQ:SMMT) and Logistic Properties of the Americas (NYSEAMERICAN:LPA) are related companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Summit Therapeutics currently has a consensus target price of $26.15, suggesting a potential upside of 100.88%. Logistic Properties of the Americas has a consensus target price of $7.50, suggesting a potential upside of 155.10%. Given Logistic Properties of the Americas' higher probable upside, analysts clearly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Summit Therapeutics had 11 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 14 mentions for Summit Therapeutics and 3 mentions for Logistic Properties of the Americas. Logistic Properties of the Americas' average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.35 indicating that Logistic Properties of the Americas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Logistic Properties of the Americas	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Logistic Properties of the Americas has a net margin of 6.31% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 1.08% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Logistic Properties of the Americas	6.31%	1.08%	0.49%

Summit Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Logistic Properties of the Americas has a beta of 5.38, indicating that its stock price is 438% more volatile than the broader market.

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Logistic Properties of the Americas	$50.13M	1.85	$10.50M	N/A	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of Logistic Properties of the Americas shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Logistic Properties of the Americas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Revolution Medicines?

Summit Therapeutics (NASDAQ:SMMT) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Revolution Medicines' return on equity of -83.22% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Revolution Medicines	N/A	-83.22%	-59.06%

Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

Summit Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Summit Therapeutics presently has a consensus price target of $26.15, indicating a potential upside of 100.88%. Revolution Medicines has a consensus price target of $144.67, indicating a potential downside of 22.85%. Given Summit Therapeutics' higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Revolution Medicines had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 23 mentions for Revolution Medicines and 14 mentions for Summit Therapeutics. Revolution Medicines' average media sentiment score of 1.39 beat Summit Therapeutics' score of 0.35 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	19 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Summit Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

BeOne Medicines presently has a consensus target price of $394.00, indicating a potential upside of 24.68%. Summit Therapeutics has a consensus target price of $26.15, indicating a potential upside of 100.88%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

BeOne Medicines has a net margin of 8.94% compared to Summit Therapeutics' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Summit Therapeutics	N/A	-168.94%	-141.92%

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.49	$286.93M	$4.47	70.70
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

In the previous week, BeOne Medicines and BeOne Medicines both had 14 articles in the media. BeOne Medicines' average media sentiment score of 0.90 beat Summit Therapeutics' score of 0.35 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats Summit Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Teva Pharmaceutical Industries has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.33	$1.41B	$0.60	58.41
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Summit Therapeutics' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Summit Therapeutics	N/A	-168.94%	-141.92%

Teva Pharmaceutical Industries presently has a consensus target price of $42.00, suggesting a potential upside of 19.84%. Summit Therapeutics has a consensus target price of $26.15, suggesting a potential upside of 100.88%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 35 more articles in the media than Summit Therapeutics. MarketBeat recorded 49 mentions for Teva Pharmaceutical Industries and 14 mentions for Summit Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 0.77 beat Summit Therapeutics' score of 0.35 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	27 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Teva Pharmaceutical Industries beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.39B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-11.63	7.38	282.27	24.66
Price / Sales	N/A	1,190.93	563.88	76.67
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	15.32	16.79	10.93	6.07
Net Income	-$1.08B	-$12.56M	$3.49B	$347.99M
7 Day Performance	-0.61%	-1.79%	-0.61%	-0.42%
1 Month Performance	-15.56%	-8.42%	-3.75%	-4.80%
1 Year Performance	-51.90%	48.61%	62.10%	18.61%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	3.4752 of 5 stars	$13.02 flat	$26.15 +100.9%	-51.9%	$10.39B	N/A	N/A	110	Gap Up
MRK Merck & Co., Inc.	4.6846 of 5 stars	$131.06 +0.4%	$133.94 +2.2%	+64.6%	$322.26B	$65.01B	36.92	75,000	Trending News Upcoming Earnings Dividend Announcement
LPA Logistic Properties of the Americas	4.5031 of 5 stars	$3.01 +3.8%	$7.50 +149.2%	-52.7%	$91.69M	$50.13M	30.10	30	Gap Up
RVMD Revolution Medicines	1.9712 of 5 stars	$189.23 +0.3%	$144.67 -23.5%	+412.0%	$40.13B	$11.58M	N/A	250	Positive News Upcoming Earnings Gap Up
ONC BeOne Medicines	4.7057 of 5 stars	$325.90 -0.3%	$394.00 +20.9%	+5.7%	$35.85B	$5.34B	72.91	12,000	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, ONC, and TEVA

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Summary

How does Summit Therapeutics compare to BeOne Medicines?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, ONC, and TEVA

How does Summit Therapeutics compare to Merck & Co., Inc.?

Is SMMT or MRK more profitable?

Which has more risk & volatility, SMMT or MRK?

Do analysts recommend SMMT or MRK?

Which has higher valuation & earnings, SMMT or MRK?

Does the media refer more to SMMT or MRK?

Do insiders & institutionals hold more shares of SMMT or MRK?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Do analysts rate SMMT or LPA?

Does the media favor SMMT or LPA?

Is SMMT or LPA more profitable?

Which has more volatility & risk, SMMT or LPA?

Which has preferable valuation & earnings, SMMT or LPA?

Do institutionals & insiders hold more shares of SMMT or LPA?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Is SMMT or RVMD more profitable?

Which has better valuation & earnings, SMMT or RVMD?

Which has more volatility and risk, SMMT or RVMD?

Do analysts rate SMMT or RVMD?

Do institutionals and insiders believe in SMMT or RVMD?

Does the media refer more to SMMT or RVMD?

Summary

How does Summit Therapeutics compare to BeOne Medicines?

Which has more volatility & risk, ONC or SMMT?

Do analysts rate ONC or SMMT?

Is ONC or SMMT more profitable?

Do institutionals & insiders believe in ONC or SMMT?

Which has stronger valuation & earnings, ONC or SMMT?

Does the media prefer ONC or SMMT?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Which has stronger earnings and valuation, TEVA or SMMT?

Do institutionals and insiders hold more shares of TEVA or SMMT?

Is TEVA or SMMT more profitable?

Do analysts rate TEVA or SMMT?

Which has more risk and volatility, TEVA or SMMT?

Does the media refer more to TEVA or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools